Novel small-molecule inhibitors, neutralizing antibodies, or anti-sense nucleotides disrupting COL4A1 and COL13A1 should be developed and tested in patients with bladder cancer refractive to conventional therapies. The gene discussed is COL13A1; the disease is urinary bladder carcinoma.